Low-dose Nab-Paclitaxel-based Combination Chemotherapy in Heavily-Pretreated Pancreatic or Ampullary Cancer Patients: Taiwanese Single-Center Case Series.
Shih-Hung Yang,Jhe-Cyuan Guo,Chiun Hsu,Chih-Hung Hsu,Sung Hsin Kuo,Ann-Lii Cheng,Kun-Huei Yeh
DOI: https://doi.org/10.1200/jco.2016.34.15_suppl.e15695
IF: 45.3
2016-01-01
Journal of Clinical Oncology
Abstract:e15695 Background: In heavily-pretreated periampullary cancer patients, the prognosis remains poor, and no standard salvage therapy exists. Methods: Pancreatic or ampullary cancer patients who had been treated with nab-paclitaxel (Nab-P) for palliation after failure of gemcitabine and/or fluoropyrimidines were retrospectively reviewed at National Taiwan University Hospital among Year 2013-2015. Results: Thirty-nine patients were identified (M/F: 27/12; median age of years: 64, range 24-86; pancreas/ampulla: 36/3). Initial stage was I, II, III, IV in 1, 20, 3, and 15 patients, respectively. Twenty-one patients had received curative surgery. Median recurrence-free survival was 3.2 (95% CI: 2.7-3.7) months. Adjuvant therapy had been given in 16 patients. Median prior lines of treatment were 2 (range 1-6). Nineteen (49%) patients had ECOG performance status ≥ 2. Best response to prior therapy was complete or partial response (PR) in 6 patients and stable disease (SD) in 8 patients. Namely, the Nab-P-based regimens included Nab-P/gemcitabine (Nab-PG, N = 27), Nab-P/platinum/5-FU analogs (Nab-PPF, N = 7), Nab-P/5-FU analogs (N = 3), Nab-P/gemcitabine/S-1 (N = 1), and Nab-P/irinotecan/5-FU (Nab-PIF, N = 1). The median dose of nab-paclitaxel was 65 (range 51-128) mg/m2/dose with the schedule of D1/15, D1/8, and D1/8/15 in 22, 14, and 3 patients, respectively. One PR and four SD were observed with Nab-PG, one SD with Nab-PPF, and one SD with Nab-PIF. Progressive disease was observed in 22 patients; 10 patients were not evaluable. Median progression-free survival was 2.6 (95% CI: 2.1-3.0) months. Median overall survival was 5.1 (95% CI: 4.4-5.9) months. Hematological toxicities were significant with ≥ Gr3 leucopenia and/or neutropenia in 4 patients, and anemia in 5 patients. Granulocyte-colony stimulating factor was used in 21 patients for prophylaxis or rescue. Significant ( ≥ Gr3) non-hematological toxicities except infection (N = 7) were not frequent. Conclusions: In heavily-pretreated periampullary cancer patients, combination chemotherapy with relatively low doses of Nab-P is fairly tolerable with modest efficacy.